The report expects Gland to outperform in the US market with 23% YoY growth supported by Flovent HFA exclusivity, and forecasts 42% YoY EBITDA growth.
Read this note →Gland Pharma Limited
NSE GLAND BSE 543245 INE068V01023
0 filings · 0 analysed
3,302.40
+73.38%
over 6 months
-
The report expects Gland to outperform in the US market with 23% YoY growth supported by Flovent HFA exclusivity, and forecasts 42% YoY EBITDA growth.
-
The report mentions an investor is likely to sell 15 lakh shares (~0.8% stake) via block deal at a floor price of ₹2,990/share for ~₹450 crore.
Prices from Yahoo Finance, NSE close, delayed — indicative only, not for dealing. Solid markers sit on the exchange's own timestamp.
What the desks said
The report mentions an investor is likely to sell 15 lakh shares (~0.8% stake) via block deal at a floor price of ₹2,990/share for ~₹450 crore.
Read this note →Announcement timeline
No filings stored for this company yet.
Never miss the next one.
Orivam emails what the research desks published each trading morning, attributed and linked to the original notes. Free.
Get the daily brief